The forging of bureaucratic autonomy: Reputations, networks, and policy innovation in executive agencies, 1862-1928 D Carpenter Princeton University Press, 2002 | 2772 | 2002 |
Reputation and power: organizational image and pharmaceutical regulation at the FDA D Carpenter Princeton University Press, 2014 | 1620 | 2014 |
Reputation and public administration DP Carpenter, GA Krause Public administration review 72 (1), 26-32, 2012 | 722 | 2012 |
Preventing regulatory capture: Special interest influence and how to limit it D Carpenter, DA Moss Cambridge University Press, 2013 | 716 | 2013 |
Global health security: the wider lessons from the west African Ebola virus disease epidemic DL Heymann, L Chen, K Takemi, DP Fidler, JW Tappero, MJ Thomas, ... The Lancet 385 (9980), 1884-1901, 2015 | 602 | 2015 |
The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect P Cram, AM Fendrick, J Inadomi, ME Cowen, D Carpenter, S Vijan Archives of Internal Medicine 163 (13), 1601-1605, 2003 | 480 | 2003 |
A formal model of learning and policy diffusion C Volden, MM Ting, DP Carpenter American Political Science Review 102 (3), 319-332, 2008 | 473 | 2008 |
Groups, the media, agency waiting costs, and FDA drug approval DP Carpenter American Journal of Political Science, 490-505, 2002 | 416 | 2002 |
Failure of investigational drugs in late-stage clinical development and publication of trial results TJ Hwang, D Carpenter, JC Lauffenburger, B Wang, JM Franklin, ... JAMA internal medicine 176 (12), 1826-1833, 2016 | 412 | 2016 |
Protection without capture: Product approval by a politically responsive, learning regulator DP Carpenter American Political Science Review 98 (4), 613-631, 2004 | 302 | 2004 |
Adaptive signal processing, hierarchy, and budgetary control in federal regulation DP Carpenter American Political Science Review 90 (2), 283-302, 1996 | 293 | 1996 |
Friends, brokers, and transitivity: Who informs whom in Washington politics? DP Carpenter, KM Esterling, DMJ Lazer The journal of Politics 66 (1), 224-246, 2004 | 272 | 2004 |
Drug-review deadlines and safety problems D Carpenter, EJ Zucker, J Avorn New England Journal of Medicine 358 (13), 1354-1361, 2008 | 233 | 2008 |
The political economy of FDA drug review: processing, politics, and lessons for policy DP Carpenter Health affairs 23 (1), 52-63, 2004 | 171 | 2004 |
Transactional authority and bureaucratic politics D Carpenter, GA Krause Journal of Public Administration Research and Theory 25 (1), 5-25, 2015 | 165 | 2015 |
Are close elections random? J Grimmer, E Hersh, B Feinstein, D Carpenter Unpublished manuscript, 1-38, 2011 | 162 | 2011 |
The strength of weak ties in lobbying networks: Evidence from health-care politics in the United States DP Carpenter, KM Esterling, DMJ Lazer Journal of Theoretical Politics 10 (4), 417-444, 1998 | 160 | 1998 |
The strength of strong ties: A model of contact-making in policy networks with evidence from US health politics D Carpenter, K Esterling, D Lazer Rationality and Society 15 (4), 411-440, 2003 | 152 | 2003 |
Political learning from rare events: Poisson inference, fiscal constraints, and the lifetime of bureaus DP Carpenter, DE Lewis Political Analysis 12 (3), 201-232, 2004 | 146 | 2004 |
Is health politics different? D Carpenter Annual Review of Political Science 15 (1), 287-311, 2012 | 141 | 2012 |